Identification
Name Aflibercept
Accession Number DB08885
Type biotech
Description Aflibercept is a recombinant fusion protein that comprises of two main components: the vascular endothelial growth factor (VEGF) binding portions from the extracellular domains of human VEGF receptors 1 and 2 which is then fused to the Fc portion of human IgG1. Aflibercept, as an ophthalmic agent, is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Ziv-aflibercept, under the brand name Zaltrap, was developed as an injection for treatment of metastatic colorectal cancer. FDA approved in November 18, 2011 and EMA approved in November 2012.
Structure
Categories (*)
Molecular Weight 115 kDa
Groups approved
Monoisotopic Weight Not Available
Pharmacology
Indication The opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.
Mechanism of action Ablibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer.
Absorption In patients with wet AMD and CRVO, the mean peak plasma concentration (Cmax) was 0.02 mcg/mL and 0.05 mcg/mL respectively. These concentrations were reached in 1 to 3 days. Aflibercept did not accumulate when administered as repeated doses intravitreally every 4 weeks.
Protein binding Not Available
Biotransformation Because aflibercept is a protein, it is expected to be broken down via proteolysis into smaller peptides and amino acids. The cytochrome P450 enzyme system is not involved in the metabolism of aflibercept.
Route of elimination Aflibercept is eliminated through target-mediated deposition via binding to free endogenous VEGF and metabolism via proteolysis.
Toxicity For all intravitreal VEGF inhibitors, there is increased risk of stroke and myocardial infarction. An increase in intraocular pressure may also occur. When used intravenously, most common adverse reactions were leukopenia, diarrhea, neutropenia, proteinuria, AST increased, stomatitis, fatigue, thrombocytopenia, ALT increased, hypertension, weight decreased, decreased appetite, epistaxis, abdominal pain, dysphonia, serum creatinine increased, and headache.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions Not Available
Food Interactions Not Available
Vascular endothelial growth factor A
Name Vascular endothelial growth factor A
Gene Name VEGFA
Pharmacological action yes
Actions binder
References
  • Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW: Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012 Aug;154(2):222-6. doi: 10.1016/j.ajo.2012.04.020. - Pubmed
DTHybrid score 0.9777
Placenta growth factor
Name Placenta growth factor
Gene Name PGF
Pharmacological action yes
Actions binder
References
  • Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW: Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012 Aug;154(2):222-6. doi: 10.1016/j.ajo.2012.04.020. - Pubmed
DTHybrid score 1.1355
Vascular endothelial growth factor B
Name Vascular endothelial growth factor B
Gene Name Not Available
Pharmacological action yes
Actions binder
References
  • Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW: Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012 Aug;154(2):222-6. doi: 10.1016/j.ajo.2012.04.020. - Pubmed
DTHybrid score Not Available
Id Partner name Gene Name Score
1334 Tissue factor pathway inhibitor TFPI 0.0471
1719 Heparanase HPSE 0.0414
2058 P-selectin SELP 0.0373
309 Antithrombin-III SERPINC1 0.0304
230 ATP-binding cassette transporter sub-family C member 8 ABCC8 0.0257
587 Serum albumin ALB 0.0246
4411 DNA protection during starvation protein dps 0.0197
5423 UPF0010 protein HI1317 HI_1317 0.0197
3780 Lipoprotein nlpI precursor nlpI 0.0197
5424 Endonuclease VIII-like 1 NEIL1 0.0197
5787 Angiopoietin-1 receptor TEK 0.0182
4757 Cytochrome P450 2C9 CYP2C9 0.0178
3164 Biotin synthase bioB 0.0173
3186 Soluble calcium-activated nucleotidase 1 CANT1 0.0172
5036 Small inducible cytokine A8 CCL8 0.017
4385 Cytochrome c' Not Available 0.017
4967 Cytochrome c' cycA 0.017
5038 Cytochrome c' Not Available 0.017
5223 Cytochrome c' cycP 0.017
5012 Ig lambda chain V-II region MGC Not Available 0.017
3583 6-phosphogluconolactonase pgl 0.0159
6104 Dimethylaniline monooxygenase [N-oxide-forming] 1 FMO1 0.0157
3221 Cytochrome c4 cc4 0.0156
3259 Autolysin lytA 0.0151
5023 Glycoside hydrolase Not Available 0.0148
5024 Glycoside hydrolase Not Available 0.0148
4771 Dissimilatory copper-containing nitrite reductase nir 0.0148
5006 RNASE4 protein RNASE4 0.0148
6016 Cytochrome P450 2C19 CYP2C19 0.0146
113 S-adenosylmethionine decarboxylase proenzyme AMD1 0.0145
1654 Interleukin-1 beta IL1B 0.0145
844 Epidermal growth factor receptor EGFR 0.0145
4905 Cytochrome c2 Not Available 0.0143
4939 Cytochrome c2 cycA 0.0143
4964 Cytochrome c2 cycA 0.0143
4979 Cytochrome c2 cycA 0.0143
6673 Cytochrome c2 cycA 0.0143
3817 Complement C1q subcomponent subunit C C1QC 0.0138
3816 Complement C1q subcomponent subunit B C1QB 0.0138
3815 Complement C1q subcomponent subunit A C1QA 0.0138
6101 Dimethylaniline monooxygenase [N-oxide-forming] 3 FMO3 0.0137
494 Caspase-1 CASP1 0.0136
1102 Low affinity immunoglobulin gamma Fc region receptor III-B FCGR3B 0.0136
3818 Low affinity immunoglobulin gamma Fc region receptor III-A FCGR3A 0.0136
3819 Low affinity immunoglobulin gamma Fc region receptor II-a FCGR2A 0.0136
3821 Low affinity immunoglobulin gamma Fc region receptor II-c FCGR2C 0.0136
3814 Complement C1r subcomponent C1R 0.0136
2149 Angiogenin ANG 0.0136
3820 Low affinity immunoglobulin gamma Fc region receptor II-b FCGR2B 0.0135
784 High affinity immunoglobulin gamma Fc receptor I FCGR1A 0.013
1507 Cytochrome c CYCS 0.0126
3030 Salivary alpha-amylase AMY1A 0.0123
1374 Natriuretic peptides B NPPB 0.0122
1827 Gap junction alpha-1 protein GJA1 0.0121
1908 Vascular cell adhesion protein 1 VCAM1 0.0121
2723 Cholera enterotoxin subunit B ctxB 0.0118
22 30S ribosomal protein S4 rpsD 0.0117
6714 30S ribosomal protein S4 rpsD 0.0117
2077 Caspase-3 CASP3 0.0116
6374 Disintegrin and metalloproteinase domain-containing protein 28 ADAM28 0.0116
65 Matrix metalloproteinase-9 Not Available 0.0112
2430 Chondroitinase B cslB 0.0111
140 30S ribosomal protein S9 rpsI 0.011
6719 30S ribosomal protein S9 rpsI 0.011
6725 30S ribosomal protein S9 rpsI 0.011
1181 Alpha-1-acid glycoprotein 1 ORM1 0.0103
194 NADH dehydrogenase [ubiquinone] 1 subunit C2 NDUFC2 0.0103
275 Arachidonate 5-lipoxygenase ALOX5 0.0098
4513 Pancreatic alpha-amylase AMY2A 0.0098
862 Multidrug resistance-associated protein 1 ABCC1 0.0097
4512 Cytochrome P450 3A4 CYP3A4 0.0095
1732 ATP-binding cassette sub-family G member 2 ABCG2 0.0089
1024 Solute carrier family 22 member 11 SLC22A11 0.008
6143 Solute carrier family 22 member 7 SLC22A7 0.0079
6142 Solute carrier family 22 member 8 SLC22A8 0.007
101 Potassium voltage-gated channel subfamily H member 2 KCNH2 0.0064
3947 Xanthine dehydrogenase/oxidase XDH 0.0064
1729 Solute carrier family 22 member 6 SLC22A6 0.0064
193 Beta-1 adrenergic receptor ADRB1 0.0057
766 Beta-2 adrenergic receptor ADRB2 0.0056
556 Alpha-1A adrenergic receptor ADRA1A 0.005
20 Prostaglandin G/H synthase 1 PTGS1 0.0048
6024 Cytochrome P450 1A1 CYP1A1 0.0048
6013 Cytochrome P450 2E1 CYP2E1 0.0045
4200 Cytochrome P450 1A2 CYP1A2 0.004
1588 Multidrug resistance protein 1 ABCB1 0.0038
4119 Cytochrome P450 2D6 CYP2D6 0.0038